Zhitong Finance App News, Shiyao Group (01093) announced that SYH2056 tablets (this product) developed by the Group are intended to treat depression. A phase I clinical trial (research plan number: SYH2056-001) to evaluate the safety, tolerability and pharmacokinetic characteristics of a single oral administration of this product in Chinese health participants and food effects studies has been officially launched in China.

This product is a small molecule 5-HT2A partial agonist developed by the Group. While exerts partial stimulatory activity on 5-HT2A receptors, the product maintains good synaptic plasticity on neurons; a single dose can exert antidepressant effects comparable or superior to similar products in various animal models. Furthermore, preclinical studies have shown that the product has low risks associated with off-target, hallucinogenic, and drug dependency.

SYH2056-001 is a phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and food effects studies of a single oral administration of this product in Chinese health participants. The main purpose is to evaluate the safety, tolerability, pharmacokinetics, and effects of single oral administration of this product by healthy participants. Currently, the recruitment and screening of participants is being actively promoted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.